Reviewed listing: NASDAQ:MCRB · Analysis dated Oct 27, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Seres develops oral medicines made from selected live bacteria, intended to affect the intestinal environment, for people with serious diseases. Its former approved product, VOWST, was sold; it currently has no approved drug of its own generating ongoing sales revenue.
What supports the business?
In a small study without a comparison group, diarrhea symptoms improved in 12 of 15 people by day 15, without their needing certain immune-suppressing medications. This is an early signal, but not yet proof of an effective treatment.
What could improve?
A partner or secured funding could enable further studies of SER-155. The early results are encouraging, but whether they will lead to an approved drug remains uncertain.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 1.80 USD per share, the value cannot be reliably classified as cheap or expensive. Seres does not yet have an approved drug of its own, and potential value depends mainly on studies that have not yet been funded.
What is the main risk?
Seres continues to burn cash, and its study of SER-155 in stem cell transplants is suspended due to a lack of funding. The second Nestlé payment of 12.5 million USD, due on 1 October 2026, is not confirmed as received in the official communications reviewed; further delays or new shares could severely dilute existing holdings.
What is the overall assessment?
Seres has an early, as-yet-unconfirmed clinical signal, but no approved drug of its own with ongoing sales revenue. Cash burn, a financing gap, and the paused study make the overall proposition at the specified price unconvincing at present; whether the second Nestlé payment has been received remains unclear in the reviewed official announcements.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in